.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Fish and Richardson
Cantor Fitzgerald
AstraZeneca
US Army
US Department of Justice
Medtronic
UBS
Accenture
Farmers Insurance

Generated: June 28, 2017

DrugPatentWatch Database Preview

Crizotinib - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for crizotinib and what is the scope of crizotinib patent protection?

Crizotinib
is the generic ingredient in one branded drug marketed by Pf Prism Cv and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Crizotinib has one hundred and twenty-seven patent family members in forty-six countries.

One supplier is listed for this compound.

Summary for Generic Name: crizotinib

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list51
Clinical Trials: see list93
Patent Applications: see list118
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:crizotinib at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-001Aug 26, 2011RXYesNo► Subscribe► Subscribe
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-002Aug 26, 2011RXYesYes► Subscribe► Subscribe
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-001Aug 26, 2011RXYesNo7,230,098► SubscribeY ► Subscribe
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-001Aug 26, 2011RXYesNo7,858,643► SubscribeYY ► Subscribe
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-001Aug 26, 2011RXYesNo8,217,057► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: crizotinib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,106,197Aminoheteroaryl compounds as protein kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: crizotinib

Country Document Number Estimated Expiration
Russian Federation2008122471► Subscribe
China103265477► Subscribe
European Patent Office1603570► Subscribe
South Korea20070038562► Subscribe
African Regional IP Organization (ARIPO)200503383► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CRIZOTINIB

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90008-9Sweden► SubscribePRODUCT NAME: CRIZOTINIB INKLUSIVE ETT FARMACEUTISKT GODTAGBART SALT, SOLVAT ELLER HYDRAT DAERAV; REG. NO/DATE: EU/1/12/793/001 20121023
155Luxembourg► SubscribePRODUCT NAME: CRIZOTINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE
00587Netherlands► SubscribePRODUCT NAME: CRIZOTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023
2013 00009Denmark► Subscribe
C0015France► SubscribePRODUCT NAME: CRIZOTINIB ET SES SELS, HYDRATES ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/793/001 20121023
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
QuintilesIMS
Daiichi Sankyo
Teva
US Department of Justice
Boehringer Ingelheim
Chinese Patent Office
Chubb
Moodys
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot